Abstract | INTRODUCTION: AREAS COVERED: Research over the past two decades suggests several diseases in the three areas noted above which upamostat may be active. Upamostat has been studied clinically against several cancers and for outpatient treatment of COVID-19. Preclinical and clinical pharmacokinetic and metabolism studies demonstrate good bioavailability, sustained tissue levels, and high concentrations of the active moiety, WX-UK1, in stool, potentially important for treatment of gastrointestinal diseases. Clinical studies suggest activity against SARS-CoV-2; results against pancreatic cancer are also encouraging, though studies in both indications are not definitive. The drug was very well tolerated for periods of 2 weeks to several months. EXPERT OPINION:
|
Authors | T F Plasse, R Fathi, C Fehrmann, G A McComsey |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Pg. 1-9
(Nov 16 2023)
ISSN: 1744-7658 [Electronic] England |
PMID | 37970658
(Publication Type: Journal Article, Review)
|